Correlation Between Sonnet Biotherapeutics and Virpax Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Sonnet Biotherapeutics and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sonnet Biotherapeutics and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sonnet Biotherapeutics Holdings and Virpax Pharmaceuticals, you can compare the effects of market volatilities on Sonnet Biotherapeutics and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sonnet Biotherapeutics with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sonnet Biotherapeutics and Virpax Pharmaceuticals.

Diversification Opportunities for Sonnet Biotherapeutics and Virpax Pharmaceuticals

0.7

Correlation Coefficient

Sonnet Biotherapeutics  Virpax Pharmaceuticals

Poor diversification

The 3 months correlation between Sonnet and Virpax is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Sonnet Biotherapeutics Holding and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and Sonnet Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sonnet Biotherapeutics Holdings are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of Sonnet Biotherapeutics i.e., Sonnet Biotherapeutics and Virpax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Sonnet Biotherapeutics and Virpax Pharmaceuticals

Given the investment horizon of 90 days Sonnet Biotherapeutics Holdings is expected to under-perform the Virpax Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Sonnet Biotherapeutics Holdings is 1.37 times less risky than Virpax Pharmaceuticals. The stock trades about -0.1 of its potential returns per unit of risk. The Virpax Pharmaceuticals is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  1,100  in Virpax Pharmaceuticals on October 5, 2024 and sell it today you would lose (1,062) from holding Virpax Pharmaceuticals or give up 96.55% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	99.79%
Values	Daily Returns

Sonnet Biotherapeutics Holding  vs.  Virpax Pharmaceuticals

Sonnet Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Virpax Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Virpax Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Sonnet Biotherapeutics and Virpax Pharmaceuticals

The main advantage of trading using opposite Sonnet Biotherapeutics and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sonnet Biotherapeutics position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.

The idea behind Sonnet Biotherapeutics Holdings and Virpax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.